Περίληψη:
In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipidlowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting. © The Author(s) 2017. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved.
Συγγραφείς:
Cicero, A.F.G.
Colletti, A.
Bajraktari, G.
Descamps, O.
Djuric, D.M.
Ezhov, M.
Fras, Z.
Katsiki, N.
Langlois, M.
Latkovskis, G.
Panagiotakos, D.B.
Paragh, G.
Mikhailidis, D.P.
Mitchenko, O.
Paulweber, B.
Pella, D.
Pitsavos, C.
Reiner, Z.
Ray, K.K.
Rizzo, M.
Sahebkar, A.
Serban, M.-C.
Sperling, L.S.
Toth, P.P.
Vinereanu, D.
Vrablík, M.
Wong, N.D.
Banach, M.
on behalf of the International Lipid Expert Panel (ILEP)
Λέξεις-κλειδιά:
alpha tocopherol; anthocyanin; antilipemic agent; berberine; beta glucan; carnitine; chitosan; cholestin; conjugated linoleic acid; curcumin; Cynara acolymus extract; gamma oryzanol; hydroxymethylglutaryl coenzyme A reductase inhibitor; ispagula; lipid; low density lipoprotein cholesterol; mannan; nutraceutical; omega 3 fatty acid; pantethine; phycocyanin; phytosterol; policosanol; probiotic agent; silymarin; sinecatechins; soybean protein; stanozolol; unclassified drug; unindexed drug; xuezhikang; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; phytochemical; probiotic agent; triacylglycerol; unsaturated fatty acid, artichoke; Article; cardiovascular disease; cardiovascular risk; Chlorella; Citrus bergania; citrus fruit; clinical practice; dietary fiber; drug efficacy; drug mechanism; drug safety; drug tolerability; dyslipidemia; economic aspect; endothelium; garlic; Glycyrrhiza; health care personnel; human; intestine absorption; lifestyle modification; lupin; Momordica charantia; nonhuman; patient care; physician; prevalence; primary medical care; pulse wave; randomized controlled trial (topic); risk factor; risk reduction; Silybum marianum; Spirulina; blood; cardiovascular disease; dietary supplement; drug effects; drug interaction; dyslipidemia; evidence based medicine; lifestyle; liver; meta analysis (topic); metabolism; observational study, Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Drug Interactions; Dyslipidemias; Evidence-Based Medicine; Fatty Acids, Unsaturated; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Life Style; Liver; Meta-Analysis as Topic; Observational Studies as Topic; Phytochemicals; Probiotics; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides
